PP
ABCL icon

Paloma Partners’s AbCellera Biologics ABCL Stock Holding History

Paloma Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-61,587
Closed -$600K – 1061
2022
Q1 		$600K Sell
61,587
-25,580
-29% -$242K 0.02% 652
2021
Q4 		$1.25M Buy
+87,167
New +$1.32M 0.02% 604
2021
Q2 		– Sell
-26,592
Closed -$903K – 1726
2021
Q1 		$903K Buy
+26,592
New +$1.06M 0.02% 760

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Paloma Partners's ABCL Position: Q2 2022 in Review

Paloma Partners sold out of AbCellera Biologics (ABCL) in Q2 2022, closing a stake of 61,587 shares — an estimated $600K sold.

Paloma Partners first reported a position in ABCL in Q1 2021 and held it in 3 quarters. The position peaked at $1.25M in Q4 2021. 161 funds tracked by Wall St. Rank hold ABCL as of Q2 2022.

  • Paloma Partners reported no remaining AbCellera Biologics position as of Q2 2022 after selling out during the quarter.
  • Paloma Partners sold 61,587 AbCellera Biologics shares in Q2 2022, an estimated $600K.
  • Paloma Partners first reported a position in AbCellera Biologics in Q1 2021 and held it in 3 quarters.
  • Paloma Partners's AbCellera Biologics position peaked at $1.25M in Q4 2021.
  • 161 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2022.

Based on Paloma Partners's 13F filing for Q2 2022, filed 15 Aug 2022.